Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. 2010

Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109-5637, USA. mmccrack@med.umich.edu

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately 1 year. To develop improved treatment, we have combined a Chk1/2-targeted agent, AZD7762, currently in phase I clinical trials, with gemcitabine and ionizing radiation in preclinical pancreatic tumor models. We found that in vitro AZD7762 alone or in combination with gemcitabine significantly sensitized MiaPaCa-2 cells to radiation. AZD7762 inhibited Chk1 autophosphorylation (S296 Chk1), stabilized Cdc25A, and increased ATR/ATM-mediated Chk1 phosphorylation (S345 Chk1). Radiosensitization by AZD7762 was associated with abrogation of the G(2) checkpoint as well as with inhibition of Rad51 focus formation, inhibition of homologous recombination repair, and persistent gamma-H2AX expression. AZD7762 was also a radiation sensitizer in multiple tumor xenograft models. In both MiaPaCa-2- and patient-derived xenografts, AZD7762 significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, our findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011494 Protein Kinases A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein. Protein Kinase,Kinase, Protein,Kinases, Protein
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell

Related Publications

Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
October 2004, Molecular cancer therapeutics,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
August 2014, Journal of hematology & oncology,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
September 2008, Molecular cancer therapeutics,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
February 2005, Oncogene,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
February 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
September 2021, Cancer research,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
April 1995, Cancer research,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
February 2012, Cancer research,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
November 2020, Radiation and environmental biophysics,
Meredith A Morgan, and Leslie A Parsels, and Lili Zhao, and Joshua D Parsels, and Mary A Davis, and Maria C Hassan, and Sankari Arumugarajah, and Linda Hylander-Gans, and Deborah Morosini, and Diane M Simeone, and Christine E Canman, and Daniel P Normolle, and Sonya D Zabludoff, and Jonathan Maybaum, and Theodore S Lawrence
November 2001, Oncogene,
Copied contents to your clipboard!